ST. LOUIS – Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it is making progress toward closing the planned acquisition of the Company by Merck KGaA, Darmstadt, Germany. The closing is now expected within the next two months.
On August 11, 2015, Sigma-Aldrich and Merck announced they had obtained all necessary antitrust approvals, with the approval of the European Commission (EC) being conditional upon the sale of parts of Sigma-Aldrich's solvents and inorganics business in Europe. Negotiations with potential buyers are in the final stage. Once a binding agreement has been signed, the EC must approve the buyer before Merck can complete the Sigma-Aldrich acquisition.
On September 22, 2014, Merck and Sigma-Aldrich announced they had entered into a definitive agreement under which Merck, will acquire Sigma-Aldrich for $17 billion - $140 cash per share, establishing one of the leading players in the $130 billion global life science industry.
About Sigma-Aldrich: Sigma-Aldrich, a leading Life Science and Technology company focused on enhancing human health and safety, manufactures and distributes 250,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units - Research, Applied and SAFC Commercial - Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 37 countries, has approximately 9,700 employees worldwide and had sales of $2.79 billion in 2014. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.
Media Relations, Karen Miller, 314/286-7996, email@example.com;
Investor Relations, Quintin Lai, 314/898-4643, firstname.lastname@example.org
Web Site: http://www.sigma-aldrich.com